Health
Jim Cramer: The Drug Cos. Are at Full Strength
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
Will Clover Health Investments Turn Around?
Let's take a look at 2 charts.
This Dividend Stock Might Be Just What the Doctor Ordered
Perrigo hit some bumps, but it offers deep value and dividend growth.
Jim Cramer: Looking for Gold? Go With Science
A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.
Time to Check Out Ebix
EBIX offers extensive potential gains while downside appears small.
Cannabis Companies Eyeing How Plant Could Help Autism Symptoms
After finding success in treatment for epilepsy and other conditions, some in the industry are focusing on autism spectrum disorder.
This Dividend Stock Is Good for Both Waistline and Bottom Line
As obesity rates climb higher, the quarterly dividend of Medifast should, too.
Cannabis Company Eyes Medicinal Magic of Mushrooms
Mydecine Innovations Group -- formerly known as NewLeaf -- signed an agreement with the University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences.
Jim Cramer: This Is a Brave New Economy We're In
The Fed and Treasury are set on avoiding the mistakes that doomed us in the past, and we have to invest for this new market we're in now.
Jim Cramer: The Cost of Staying Closed
We can't wait for a vaccine, but we can follow logical guidelines for staying as safe as possible, helping us avoid another Great Depression.